Research will explore the use of cord blood and menstrual blood derived stem cells.

Cryo-Cell and EndGenitor Technologies entered a collaboration to develop a combined cellular platform therapeutic for forming vasculature in injured tissues.

The study will focus on mechanisms of initiation of angiogenesis and the repair of damaged vasculature to identify the molecular and cellular components involved in vasculature formation.

The study will use cells derived from cord blood and menstrual blood, known as ECFCs® and MenSCs, respectively. ECFCs are currently in preclinical development by EndGenitor for cardiovascular and other therapeutic applications. MenSCs were developed by Cryo-Cell, who maintains intellectual property on MenSCs.

Previous articleCompounds that Block a Fatty Acid in the Brain Improve Survival in Mice with Glioblastoma-Like Disease
Next articleRapamycin Halts Tumor Growth but Also Activates a Pathway that Promotes Cancer Cell Survival